Of the possible proteins that are affected in AML, fms-like tyrosinekinase 3 (FLT3) has long been recognized as a potential therapeutic target as it affects the other signaling pathways and leads to a cascade of events. This evidence concerns the gene FLT3 and acute myeloid leukemia.